Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 0.65 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.64 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
| ▸ | STAT6 | P42226 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.63 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648689 | 0.92 | AHCY (0.59) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL31680251 | 0.91 | AHCY (0.68) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL397800 | 0.91 | AHCY (0.68) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL6671788 | 0.90 | AHCY (0.67) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL7803295 | 0.90 | AHCY (0.67) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL2040666 | 0.89 | PRMT5 (0.66) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL22326785 | 0.88 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL21413837 | 0.88 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL22326787 | 0.88 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA2AADORA2B | |
| SCHEMBL18520788 | 0.88 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | claimed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | claimed |
| CN-118946556-A | DGK targeting compounds and uses thereof | 阿维纳斯运营公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-2710145-A1 | METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS | Dxterity Diagnostics Incorporated (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8344115-B2 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | HAO, XIUJUAN | 2013-01-01 | — | — | US | disclosed |
| WO-2012158967-A1 | METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS | DXTERITY DIAGNOSTICS INCORPORATED (US) | 2012-11-22 | — | — | WO | disclosed |
| US-7671191-B2 | Methods for preparing 2-alkynyladenosine derivatives | PGX HEALTH, LLC (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2009131643-A1 | IMMUNOASSAY FOR SPECIFIC DETERMINATION OF S-ADENOSYMETHIONINE AND ANALOGS THEREOF IN BIOLOGICAL SAMPLES | MONABIO, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090263879-A1 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | HAO, XIUJUAN | 2009-10-22 | — | — | US | disclosed |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADENOSINE THERAPEUTICS, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20070265440-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-11-15 | — | — | US | disclosed |
| CN-1357002-A | Compositions for treating inflammatory responses | UNIV VIRGINIA (US) | 2002-07-03 | — | — | CN | disclosed |
| EP-1194440-A2 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6322771-B1 | PARENTERALLY ADMINISTERING TO A MAMMAL A PURINE DERIVATIVE TO DIAGNOSE CORONARY ARTERY STENOSIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-11-27 | — | — | US | disclosed |
| EP-1150991-A2 | COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010027185-A1 | Methods and compositions for treating inflammatory response | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-10-04 | — | — | US | disclosed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | disclosed |
| US-6232297-B1 | ADMINISTERING 4-AMINOPYRROLO(3,2-D)PYRIMIDINE DERIVATIVE AS ADENOSINE RECEPTOR ANTAGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-05-15 | — | — | US | disclosed |
| WO-2000078774-A2 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000044763-A2 | COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265440-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | ADORA2A, ADORA2B, LTB4R2 | AHCY 288/4885PRMT5 3539/4885WDR77 3030/4885 |
| US-20090263879-A1 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | AHCY, MAT2A, MAT1A | AHCY 1/4885PRMT5 58/4885WDR77 1189/4885 |
| US-20010027185-A1 | Methods and compositions for treating inflammatory response | LTB4R2, ADORA2A, PTGES2 | AHCY 389/4885PRMT5 3460/4885WDR77 3470/4885 |
| US-20020177695-A1 | Nucleic acid probes and methods | NUDT1, NT5C3B, NT5C2 | AHCY 228/4885PRMT5 3119/4885WDR77 2751/4885 |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADORA2A, ADORA3, ADORA1 | AHCY 116/4885PRMT5 530/4885WDR77 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.